COPENHAGEN, Jan 5 (Reuters) – Denmark’s Novo Nordisk will offer its 1.5 ​and 4 milligram Wegovy weightloss pills ‌at $149 per month to self-paying patients in ‌the United States from January 5, it said on Monday.

It will from the same date offer the highest doses ⁠of the drug ‌pill, of 9 and 25 milligram, at $299 per month, it ‍said on its website.

The price for the 4 milligram dose will rise to $199 per ​month from April 15, it ‌said.

The U.S. Food and Drug Administration on December 22 approved the pill, giving Novo Nordisk a leg up as it looks to regain lost ground ⁠from rival Eli Lilly.

The ​semaglutide pills contain the ​same active ingredient as injectable Wegovy and Ozempic, and will be ‍sold ⁠under the brand name Wegovy. Novo Nordisk already sells an oral semaglutide ⁠for type 2 diabetes, Rybelsus.

(Reporting by Jacob ‌Gronholt-Pedersen, writing by Anna Ringstrom, editing ‌by Terje Solsvik)